The pharmacokinetics of etanercept in healthy volunteers

被引:1
|
作者
Korth-Bradley, JM
Rubin, AS
Hanna, RK
Simcoe, DK
Lebsack, ME
机构
[1] Wyeth Ayerst Res, Clin Pharmacokinet, Philadelphia, PA 19101 USA
[2] Immunex Corp, Biometr, Seattle, WA 98101 USA
[3] Immunex Corp, Analyt Resources Dept, Seattle, WA 98101 USA
关键词
phamacokinetics; etanercept;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: TO describe the pharmacokinetics of etanercept when administered by subcutaneous injection in single doses to healthy volunteers, METHODS: Twenty-six healthy volunteers between 19 and 50 years of age received single doses of etanercept 25 mg by subcutaneous injection into the abdomen. Serial serum samples were collected for 21 days. An enzyme-linked immunosorbent assay with a quantitation limit of 0.3 ng/mL was used to measure the drug concentrations. RESULTS: Etanercept was well tolerated by healthy volunteers. A one-compartment model was found to best describe the concentration-time data and was used to determine the pharmacokinetic parameters. Etanercept is slowly absorbed from the site of injection with a time of peak concentration (+/- SD) of 51 +/- 14 hours; peak concentration was 1.46 +/- 0.72 mg/L. The AUC was 235 +/- 98 mg.h/L, apparent clearance was 132 +/- 85 mL/h, apparent volume of distribution was 12 +/- 6 L, and the half-life was 68 +/- 19 hours. CONCLUSIONS: Etanercept was slowly absorbed and slowly eliminated after subcutaneous administration. Dosing at the recommended rate of 25 mg twice weekly would be expected to result in concentrations of approximately 3 mg/L. Intersubject variability for apparent clearance in healthy volunteers was 64%.
引用
收藏
页码:161 / 164
页数:4
相关论文
共 50 条
  • [1] The comparability of etanercept pharmacokinetics in healthy Japanese and American subjects
    Kawai, S
    Sekino, H
    Yamashita, N
    Tsuchiwata, S
    Liu, HJ
    Korth-Bradley, JM
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (04): : 418 - 423
  • [2] Comparative Pharmacokinetics of HD203, a Biosimilar of Etanercept, with Marketed Etanercept (Enbrel ®)A Double-Blind, Single-Dose, Crossover Study in Healthy Volunteers
    So Jeong Yi
    Sung Eun Kim
    Min-Kyu Park
    Seo Hyun Yoon
    Joo-Youn Cho
    Kyoung Soo Lim
    Sang-Goo Shin
    In-Jin Jang
    Kyung-Sang Yu
    BioDrugs, 2012, 26 : 177 - 184
  • [3] A novel model for the pharmacokinetic studies of bevacizumab and etanercept in healthy volunteers and patients
    Li, Meizhen
    Qiang, Wei
    Hu, Li
    Wang, Lei
    Cheng, Zeneng
    BIOCHEMICAL PHARMACOLOGY, 2017, 145 : 169 - 177
  • [4] Pharmacokinetics and safety of intravitreally delivered etanercept
    Sascha Fauser
    Hubert Kalbacher
    Nils Alteheld
    Kan Koizumi
    Tim U. Krohne
    Antonia M. Joussen
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2004, 242 : 582 - 586
  • [5] Population pharmacokinetics of rhTNFR-Fc in healthy Chinese volunteers and in Chinese patients with Ankylosing spondylitis
    Fang, Yi
    Li, Lu-jin
    Wang, Rui
    Huang, Feng
    Song, Hai-feng
    Tang, Zhong-ming
    Li, Yu-zhen
    Guan, Hua-shi
    Zheng, Qing-shan
    ACTA PHARMACOLOGICA SINICA, 2010, 31 (11) : 1500 - 1507
  • [6] Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis
    Nestorov, Ivan
    Zitnik, Ralph
    DeVries, Todd
    Nakanishi, Arline M.
    Wang, Andrea
    Banfield, Christopher
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (04) : 435 - 445
  • [7] Intrapatient Variability in the Pharmacokinetics of Etanercept Maintenance Treatment
    van Bezooijen, Ji S.
    Schreurs, Marco W. J.
    Koch, Birgit C. P.
    te Velthuis, Henk
    van Doorn, Martijn B. A.
    Prens, Errol P.
    van Gelder, Teun
    THERAPEUTIC DRUG MONITORING, 2017, 39 (04) : 333 - 338
  • [8] Pharmacokinetics and immunogenicity of T0001, a newly developed anti-TNFα fusion protein, in healthy volunteers
    Wang, Yitong
    Liu, Chang
    Chen, Shi
    Wang, Wei
    Dong, Lihou
    Wang, Qian
    Wang, Yan
    Zhao, Libo
    Zang, Yannan
    Xie, Zhenwei
    Liu, Yang
    Liu, Yanjun
    Song, Haifeng
    Li, Zhanguo
    Fang, Yi
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 73 (09) : 1095 - 1101
  • [9] Introduction. Chemical structure of etanercept, pharmacokinetics and mechanism of action
    Dauden, E.
    ACTAS DERMO-SIFILIOGRAFICAS, 2010, 101 : 1 - 4
  • [10] Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis
    Zhou, HH
    Mayer, PR
    Wajdula, J
    Fatenejad, S
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (11): : 1235 - 1243